Evidence map›Paper›PMID 39342363›Full record

ArticleMolecular cancer2024

Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification.

Abhishek Jain, Montana T Morris, Domenica Berardi, Trisha Arora, Xavier Domingo-Almenara, Philip B Paty, Nicholas J W Rattray, Daniel Kerekes, Lingeng Lu, Sajid A Khan and 1 more

Abstract read
In one paragraph

Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abhishek JainDepartment of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, CT, 06510, USA.
Montana T MorrisDepartment of Surgery/Surgical Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Domenica BerardiDepartment of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, CT, 06510, USA.
Trisha AroraOmics Sciences Unit, EURECAT - Technology Centre of Catalonia, Avda. Universitat 1, Reus, 43204, Catalonia, Spain.
Xavier Domingo-AlmenaraOmics Sciences Unit, EURECAT - Technology Centre of Catalonia, Avda. Universitat 1, Reus, 43204, Catalonia, Spain.
Philip B PatyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
Nicholas J W RattrayStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Daniel KerekesDepartment of Surgery/Surgical Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Lingeng LuDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College Street, New Haven, CT06510, USA.
Sajid A KhanDepartment of Surgery/Surgical Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA. sajid.khan@yale.edu.
Caroline H JohnsonDepartment of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, CT, 06510, USA. caroline.johnson@yale.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Microbial Chemical Sensing and Host ResponsesRM1GM141649 · NIGMS · YALE UNIVERSITY · PI Jason Michael Crawford, Caroline Helen Johnson · 2021 to 2026
$9.0M
American Cancer Society RSG-20-065-01-TBE]"La Caixa" Foundation (ID 100010434) via the Junior Leader Fellowship LCF/BQ/PR21/11840001 100010434Medical Research Council MR/Y010736/1NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NIGMS NIH HHS RM1 GM141649NIH HHS [1RM1GM141649-01]the European Commission's Horizon 2020 via the Innovative Training Network Marie Skłodowska-Curie COL_RES project under the grant agreement No 956279 956279the UK Royal Society IF\R1\231034
6 · The paper itself

Abstract

objectiveColorectal cancer (CRC) is conventionally classified as right sided, left sided, and rectal cancer. Clinicopathological, molecular features and risk factors do not change abruptly along the colorectum, and variations exist even within the refined subsites, which may contribute to inconsistencies in the identification of clinically relevant CRC biomarkers. We generated a CRC metabolome map to describe the association between metabolites, diagnostic and survival heterogeneity in cancers of different subsites of the colorectum.

designUtilizing 372 patient-matched tumor and normal mucosa tissues, liquid chromatography-mass spectrometry was applied to examine metabolomic profiles along seven subsites of the colorectum: cecum (n = 63), ascending colon (n = 44), transverse colon (n = 32), descending colon (n = 28), sigmoid colon (n = 75), rectosigmoid colon (n = 38), and rectum (n = 92).

results39 and 70 significantly altered metabolites (including bile acids, lysophosphatidylcholines and lysophosphatidylethanolamines) among tumors and normal mucosa, respectively, showed inter-subsite metabolic heterogeneity between CRC subsites. Gradual changes in metabolite abundances with significantly linear trends from cecum to rectum were observed: 23 tumor-specific metabolites, 30 normal mucosa-specific metabolites, and 15 metabolites in both tumor and normal mucosa, had concentration gradients across the colorectum, and is disease status dependent. The metabolites that showed a linear trend included bile acids, amino acids, lysophosphatidylcholines, and lysophosphatidylethanolamines. Comparison of tumors to patient-matched normal mucosa revealed metabolite changes exclusive to each subsite, thereby further highlighting differences in cancer metabolism across the 7 subsites of the colorectum. Furthermore, metabolites associated with survival were different and unique to each subsite. Finally, an interactive and publicly accessible CRC metabolome database was designed to enable access and utilization of this rich data resource ( https://colorectal-cancer-metabolome.com/yale-university ).

conclusionsGradual changes exist in metabolite abundances from the cecum to the rectum. The association between patient survival and distinct metabolites with anatomic subsite of the colorectum, reveals differences between cancers across the colorectum. These inter-subsite metabolic heterogeneities enrich the current understanding and substantiate previous studies that have challenged the conventional classification of right-sided, left-sided, and rectal cancers, by identifying specific metabolites that offer new biological insights into CRC subsite heterogeneity. The database designed in this study will enable researchers to delve into granular information on the CRC metabolome, which until now has not been available.

Indexed as

Colorectal NeoplasmsMetabolomeAgedBiomarkers, TumorFemaleHumansMaleMetabolomicsMiddle AgedRectumBiomarkers, TumorBiomarkersColorectal cancerMetabolome databaseMetabolomicsSubsite heterogeneity

Identifiers

PMID39342363
PMCPMC11438248

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.